Partner Headlines - NPSP

  1. Valeant Goes For Allergan; Analyst Touts Shire Option

    IBD
  2. Mid-Afternoon Market Update: Markets Turn Back As SolarCity Hangs ...

    Benzinga
  3. Mid-Day Market Update: Keurig Green Mountain Jumps On Upbeat ...

    Benzinga
  4. Mid-Morning Market Update: Markets Gain; Wendy's Profit Beats ...

    Benzinga
  5. Morning Market Losers

    Benzinga
  6. UPDATE: Canaccord Genuity Assumes Coverage on NPS Pharmaceuticals ...

    Benzinga
  7. Benzinga's Top Initiations

    Benzinga
  8. UPDATE: Jefferies Downgrades NPS Pharmaceuticals on Valuation

    Benzinga
  9. NPS Pharma Finds Big Success In Tiny Markets

    IBD
  10. Market Wrap For January 8: Fed Minutes Released

    Benzinga
  11. NPS Pharmaceuticals Receives Orphan Drug Designation for Natpara ...

    Benzinga
  12. Catalyst Stock Plunge: Ugly In Orphan Drug Land

    YCharts
  13. Mid-Afternoon Market Update: Markets Mixed as Tesla Shares Remain ...

    Benzinga
  14. NPS Pharma Says Data from STEPS 2 Trial of Gattex Supports Long-Term ...

    Benzinga
  15. Mid-Afternoon Market Update: Markets Green as Spirit Airlines ...

    Benzinga
  16. Mid-Day Market Update: Micron Shares Tumble On Downbeat Profit; ...

    Benzinga
  17. Mid-Morning Market Update: Markets Rise; JPMorgan Posts Upbeat ...

    Benzinga
  18. Orphan Drugs: No (Payer) News Is Good News

    YCharts
  19. NPS Pharma Says 53% of Natpara-Treated Patients Achieved Primary ...

    Benzinga
  20. UPDATE: Bank of America Initiates Coverage on NPS Pharmaceuticals ...

    Benzinga
  21. Benzinga's Top Initiations

    Benzinga
  22. NPS Pharma Says sNDA Submitted for Gattex STEPS 2 Data, Shows ...

    Benzinga
  23. Weekly CFO Sells Highlight: WRES, NPSP, MKTO, GRPN, RXN

    GuruFocus
  24. UPDATE: J.P. Morgan Initiates Coverage on NPS Pharmaceuticals ...

    Benzinga
  25. Benzinga's Top Initiations

    Benzinga
  26. UPDATE: Oppenheimer Raises PT on NPS Pharmaceuticals Following ...

    Benzinga
  27. Market Wrap for Friday, August 9: Stocks Close Lower To End Week

    Benzinga
  28. NPS Pharmaceuticals Chief: Why 250k-a-Year Orphan Drug is Worth ...

    YCharts
  29. You Can Expect More Insider Trading in Pharma Stocks: Here's ...

    YCharts
  30. FDA Approves NPS Gattex for Injection for Some SBS Patients

    Benzinga
  31. NPS Pharma Shares Moving Lower Amid FDA Approval of Gattex

    Benzinga
  32. NPS Pharma Publishes Pivotal Phase 3 Study of Gattex in Short ...

    Benzinga
  33. NPS Pharmaceuticals Inc. Reports Operating Results (10-Q)

    GuruFocus
  34. Benzinga Mid-Afternoon Market Update

    Benzinga
  35. Benzinga Mid-Day Market Update

    Benzinga
  36. Benzinga Mid-Morning Market Update

    Benzinga
  37. UPDATE: Jefferies & Company Reiterates Buy Rating, Raises PT ...

    Benzinga
  38. FDA Advisory Committee Unanimously Recommends Approval of Gattex® ...

    Benzinga
  39. Benzinga Mid-Day Market Update

    Benzinga
  40. Benzinga Mid-Afternoon Market Update

    Benzinga
  41. Benzinga Mid-Morning Market Update

    Benzinga
  42. UPDATE: Morgan Stanley Initiates NPS Pharmaceuticals at Overweight ...

    Benzinga
  43. Benzinga's Top Pre-Market Gainers

    Benzinga
  44. NPS Pharma Expects to File Natpara BLA in Mid 2013

    Benzinga
  45. Revestive Receives European Marketing Authorization for the Treatment ...

    Benzinga
  46. NPS Pharma Says Gattex Meeting October 16th

    Benzinga
  47. Biotechs With Upcoming PDUFA Dates

    Benzinga
  48. NPS Pharmaceuticals (NPSP) Gains 10.8% as Short Bowel Drug Moves ...

    MarketIntelligenceCenter
  49. Social Media Outlook for Friday June 22 (DRI, NPSP, R, GS)

    Benzinga
  50. Benzinga's Top Pre-Market Gainers

    Benzinga
  51. NPS Pharmaceuticals Reports NatparaTM Phase 3 Results to be Presented ...

    Benzinga
  52. NPS Pharmaceuticals Inc. Reports Operating Results (10-K)

    GuruFocus
  53. Benzinga's Top Pre-Market Gainers

    Benzinga
  54. Notable Call Options Activity in NPS Pharmaceuticals

    Benzinga
  55. Put Volume Surges on Plunging NPS Pharmaceuticals

    SchaeffersResearch
Trading Center